Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Oramed Pharmaceuticals
(NASDAQ:ORMP)
Intraday
$2.31
0.01
[0.43%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$2.31
0.01
[0.43%]
Last update: 8:19AM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Oramed Pharmaceuticals Stock (NASDAQ:ORMP)
Oramed Pharmaceuticals Stock (NASDAQ: ORMP)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, February 02, 2024
Top 4 Health Care Stocks That May Crash This Quarter
Avi Kapoor
-
Feb 2, 2024, 8:21AM
Tuesday, January 23, 2024
Oramed Pharmaceuticals Parties Intend For JV To Initiate Phase 3 Oral Insulin Trial In The U.S.; Oramed Will Be Entitled To Receive A 3% Royalty On Gross Revenues Of JV Generated From Oramed Related Assets
Charles Gross
-
Jan 23, 2024, 4:51PM
Oramed Pharmaceuticals Said On Jan 22, Co And Unit Entered Into Joint Venture Agreement With Hefei Tianhui Biotech And Technowl; Oramed And HTIT Will Initially Hold Equal Shares In JV, With Each Owning 50% Of Equity
Charles Gross
-
Jan 23, 2024, 4:50PM
Friday, September 22, 2023
Oramed Pharmaceuticals Secures $101.9M Senior Secured Note Deal With Scilex
Benzinga Newsdesk
-
Sep 22, 2023, 1:35AM
Thursday, September 21, 2023
Scilex Assumed $100M In Debt Owed To Oramed Pharmaceuticals And Issued A Promissory Note And Warrants To Oramed As Part Of The Securities Transfer.
Benzinga Newsdesk
-
Sep 21, 2023, 4:15PM
Scilex Holding Company Announces The Consummation Of The Previously Announced Purchase Of All Of The Scilex Common Shares, Preferred Shares And Warrants Owned By Sorrento Therapeutics, Inc.
Benzinga Newsdesk
-
Sep 21, 2023, 4:15PM
Wednesday, September 13, 2023
Scilex Holding Company Enters Non-Binding Term Sheets For The Purchase Of All Of The Scilex Common Shares, Preferred Shares, And Warrants Currently Owned By Sorrento Therapeutics, Inc. And is Declared New Successful Bidder
Bill Haddad
-
Sep 13, 2023, 9:02AM
Wednesday, August 02, 2023
Oramed Signs Term Sheet With HTIT To Create A Joint Venture To Advance Oral Drug Delivery Technology Globally; HTIT To Invest $60M, Oramed To Invest $10M Into JV; Shares Spike Higher
Happy Mohamed
-
Aug 2, 2023, 7:47AM
Friday, June 23, 2023
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Jun 23, 2023, 1:37PM
Why CarMax Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
-
Jun 23, 2023, 12:20PM
Dow Tumbles 250 Points; CarMax Posts Upbeat Results
Lisa Levin
-
Jun 23, 2023, 9:51AM
Wednesday, May 17, 2023
Canaccord Genuity Maintains Hold on Oramed Pharmaceuticals, Lowers Price Target to $2
Benzinga Newsdesk
-
May 17, 2023, 10:08AM
Tuesday, May 16, 2023
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
May 16, 2023, 1:31PM
Monday, May 15, 2023
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
May 15, 2023, 1:45PM
Why Oramed Pharmaceuticals Shares Are Trading Higher Today
Vandana Singh
-
May 15, 2023, 11:18AM
Oramed Announces That Its Chinese Partner, HTIT, Has Successfully Completed A Phase 3 Oral Insulin Clinical Trial And Submitted A Marketing Authorization Application In China
Benzinga Newsdesk
-
May 15, 2023, 9:07AM
Monday, May 01, 2023
Oramed Appoints Ben Shapiro To Board of Directors
Michael Horton
-
May 1, 2023, 4:48PM
Thursday, March 16, 2023
Director of Oramed Pharmaceuticals Makes $141K Buy
Benzinga Insights
-
Mar 16, 2023, 11:06AM
Oramed Pharmaceuticals Chief Scientific Officer Sold $200K In Company Stock
Benzinga Insights
-
Mar 16, 2023, 11:06AM
Thursday, February 09, 2023
Oramed Continues To Conduct Analysis Of Data From Its Discontinued Phase 3 Oral Insulin Trials
Benzinga Newsdesk
-
Feb 9, 2023, 7:57AM
Oramed Pharmaceuticals To Explore Potential Strategic Alternatives
Benzinga Newsdesk
-
Feb 9, 2023, 7:56AM
Thursday, January 19, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Jan 19, 2023, 1:35PM
Tuesday, January 17, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Jan 17, 2023, 12:17PM
Oramed Pharmaceuticals shares are trading lower after HC Wainwright & Co. downgraded the stock from Buy to Neutral.
Michael Horton
-
Jan 17, 2023, 12:14PM
Benzinga's Top Ratings Upgrades, Downgrades For January 17, 2023
Benzinga Insights
-
Jan 17, 2023, 10:01AM
HC Wainwright & Co. Downgrades Oramed Pharmaceuticals to Neutral
Benzinga Newsdesk
-
Jan 17, 2023, 6:12AM
Thursday, January 12, 2023
Gold Tops $1,900 After US CPI Report, S&P 500 Rises 0.5%
Lisa Levin
-
Jan 12, 2023, 2:28PM
Why KNOT Offshore Partners Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
-
Jan 12, 2023, 1:19PM
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Jan 12, 2023, 12:31PM
US Stocks Turn Higher; Dow Jumps 200 Points
Lisa Levin
-
Jan 12, 2023, 12:11PM
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Jan 12, 2023, 11:59AM
Dow Drops 150 Points; US Inflation Rate Slows In December
Lisa Levin
-
Jan 12, 2023, 9:54AM
Benzinga Pro's Top 5 Stocks To Watch For Thursday, January 12, 2023: DAL, PFE, C, RBLX, MNST
Benzinga Newsdesk
-
Jan 12, 2023, 9:00AM
Oramed Pharmaceuticals shares are trading lower after the company announced the ORA-D-013-1 trial did not meet its primary endpoint.
Benzinga Newsdesk
-
Jan 12, 2023, 8:51AM
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
Jan 12, 2023, 8:06AM
Why Akerna Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Jan 12, 2023, 7:54AM
Canaccord Genuity Downgrades Oramed Pharmaceuticals to Hold
Benzinga Newsdesk
-
Jan 12, 2023, 6:49AM
Oramed Pharma Shares Sink After Diabetes Candidate Fails In Phase 3 Study
Vandana Singh
-
Jan 12, 2023, 6:19AM
Oramed Pharmaceuticals, Logitech International And Some Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Lisa Levin
-
Jan 12, 2023, 6:01AM
Oramed Pharmaceuticals Shares Fall 70% Premarket After Company Reported Wednesday, Its Diabetes Trial Missed Primary Endpoint
Charles Gross
-
Jan 12, 2023, 5:15AM
Reported Late Wednesday, Oramed Pharmaceuticals Announces Top-line Results From Phase 3 Trial Of ORMD-0801 For The Treatment Of Type 2 Diabetes; The ORA-D-013-1 Trial Did Not Meet Its Primary Endpoint
Benzinga Newsdesk
-
Jan 12, 2023, 12:42AM
Thursday, January 05, 2023
Jim Cramer Says Avoid This Stock: 'Too Expensive'
Priya Nigam
-
Jan 5, 2023, 10:35AM
Wednesday, January 04, 2023
Oramed Granted U.S. Combination Therapy Patent For Oral GLP-1 & Insulin For The Treatment Of Diabetes
Benzinga Newsdesk
-
Jan 4, 2023, 7:56AM
Tuesday, January 03, 2023
Li Auto, XPeng, Nio And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Lisa Levin
-
Jan 3, 2023, 6:15AM
Thursday, December 22, 2022
Looking Into Oramed Pharmaceuticals's Return On Capital Employed
Benzinga Insights
-
Dec 22, 2022, 9:48AM
Thursday, November 17, 2022
Oramed Pharma Shares Fall After Additional Data From Oral Insulin Study
Vandana Singh
-
Nov 17, 2022, 1:12PM
Oramed Announces Additional Safety, Efficacy Data From Phase 2 Clinical Trial Of ORMD-0801 For NASH; Achieved Primary Endpoint
Benzinga Newsdesk
-
Nov 17, 2022, 12:28PM
Monday, November 14, 2022
Oramed Signs Definitive Deal With Medicox To Commercialize Oral Insulin In South Korea
Benzinga Newsdesk
-
Nov 14, 2022, 7:56AM
Thursday, November 10, 2022
Oramed Pharmaceuticals Q3 EPS $(0.18) Down From $(0.17) YoY
Benzinga Newsdesk
-
Nov 10, 2022, 5:01PM
Friday, October 07, 2022
Oramed Pharmaceuticals' Oral COVID-19 Vaccine Candidate Shows Safety, Immunogenicity In Early Study
Vandana Singh
-
Oct 7, 2022, 11:06AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch